MedTrace Logo

Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

NCT00837746 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2013-06-05

No results posted yet for this study

Summary

This study analysed and reported on the study data from three similar, risedronate studies, 1996052, 2003073, and 2003096. The objective of the study was to determine the differences in the iliac crest bone histomorphometry and bone quality in postmenopausal women who had received long term therapy with risedronate.

Conditions

Interventions

DRUG

risedronate

risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Warner Chilcott

    lead INDUSTRY

Principal Investigators

  • Ana M Balske, MD · Procter and Gamble

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00837746 on ClinicalTrials.gov